Want to see CH:BSLN full AI Analyst Report?
Top Page
Basilea Pharmaceutica
(BSLN)
Select Model
Select Model
Rating:73Outperform
Price Target:
CHF66.00
▲(25.48% Upside)
Action:Reiterated
Date:08/19/26
The score is driven primarily by improved fundamentals and cash generation, supported by a bullish earnings update with raised FY2026 guidance and stronger cash/funding metrics. The main offsets are overbought technical conditions that raise near-term pullback risk and a valuation that is not clearly cheap at a 22.5x P/E, alongside ongoing biotech execution/timing risks.
Positive Factors
Commercial Growth and Product Demand
Strong Cresemba demand supports a growing royalty and product-revenue base. Continued commercial adoption of marketed anti-infectives can improve revenue visibility and provide funding for pipeline development over the medium term.
Negative Factors
Volatile Profitability
The margin decline indicates that earnings remain sensitive to product mix, milestones and other variable items. High gross margins are encouraging, but inconsistent conversion into net profit makes medium-term earnings quality less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial Growth and Product Demand
Strong Cresemba demand supports a growing royalty and product-revenue base. Continued commercial adoption of marketed anti-infectives can improve revenue visibility and provide funding for pipeline development over the medium term.
Read all positive factors
Basilea Pharmaceutica (BSLN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF802.36M
Dividend YieldN/A
Average Volume (3M)41.01K
Price to Earnings (P/E)15.4
Beta (1Y)0.88
Revenue Growth4.74%
EPS Growth-28.96%
CountryCH
Employees200
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)4.26
Shares Outstanding13,425,260
10 Day Avg. Volume32,790
30 Day Avg. Volume41,007
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)5.22
Price to Sales (P/S)2.88
P/FCF Ratio11.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.6
Revenue Forecast (FY)CHF261.26M
Basilea Pharmaceutica Business Overview & Revenue Model
Company Description
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infect...
How the Company Makes Money
Basilea makes money primarily through (1) product-related revenue from its marketed anti-infective medicines and (2) partnering/licensing economics tied to commercialization by other companies in various territories.
1) Product-related revenue
- ...
Basilea Pharmaceutica Earnings Call Summary
Earnings Call Date:Aug 18, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Feb 16, 2027
Earnings Call Sentiment Positive
The call presented a strongly positive operational and financial picture: double-digit revenue growth, a materially higher operating profit, strengthened cash position, increased non-dilutive funding, and clear pipeline progression (two Phase III assets and new first-in-human study). Management raised full-year guidance and reiterated multi-year value creation (Agenda 2030). Key challenges are execution and timing risks around late-stage clinical readouts and regulatory clarity, increased R&D spend and near-term operating expense pressure, working capital timing effects on cash flow, and a convertible bond maturing in 2027. On balance, the positive commercial momentum, funding awards, guidance upgrades and pipeline advancement outweigh the near-term costs and timing uncertainties.Positive Updates
Revenue Growth
Total revenue grew 14% year-on-year to CHF 119 million in H1 2026, driven by commercial sales and reimbursement income.
Negative Updates
Rising Operating Expenses and R&D Investment
Operating expenses were CHF 72 million in H1 2026, increasing mainly due to progress on multiple clinical programs; company expects R&D investment to increase ~20% year-on-year, pressuring near-term operating cost base.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth
Total revenue grew 14% year-on-year to CHF 119 million in H1 2026, driven by commercial sales and reimbursement income.
Read all positive updates
Company Guidance
Basilea updated FY2026 guidance, now expecting total revenue to grow by approximately 15%, with Cresemba- and Zevtera-related revenues rising to around CHF 210 million (up from prior guidance of ~CHF 200 million) and delivering an expected cash contribution of ~CHF 180 million; the company forecasts CHF 125 million in royalties, CHF 35 million in milestone payments and CHF 50 million in product revenue for the year. Driven by the higher revenue outlook, operating profit guidance was raised to an increase of ~40% year‑on‑year (previously ~20%), equivalent to a rise from about CHF 62 million to ~CHF 72 million, while investments into R&D are still expected to increase by ~20% year‑on‑year. Management also highlighted strong balance‑sheet and funding metrics that underpin the guidance: cash and cash equivalents (plus restricted cash) of CHF 176 million, a net cash position that doubled to CHF 105 million, and substantial nondilutive R&D support with >USD 440 million committed, ~USD 165 million awarded to date (including USD 61 million in H1 2026) and over USD 350 million of potential funding still available.Basilea Pharmaceutica Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
64
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 247.44M | 232.40M | 208.54M | 157.63M | 147.76M | 148.12M |
| Gross Profit | 216.94M | 193.10M | 169.86M | 130.84M | 120.96M | 124.05M |
| EBITDA | 63.64M | 55.26M | 63.13M | 23.18M | 26.21M | 6.72M |
| Net Income | 52.34M | 40.20M | 77.59M | 10.45M | 12.15M | -6.83M |
Balance Sheet | ||||||
| Total Assets | 298.04M | 282.00M | 257.76M | 173.29M | 220.85M | 247.27M |
| Cash, Cash Equivalents and Short-Term Investments | 175.98M | 162.34M | 120.71M | 59.90M | 84.70M | 148.70M |
| Total Debt | 83.44M | 89.22M | 111.67M | 128.61M | 187.14M | 218.96M |
| Total Liabilities | 135.68M | 154.06M | 176.76M | 183.29M | 241.56M | 305.87M |
| Stockholders Equity | 162.35M | 127.94M | 81.00M | -10.00M | -20.71M | -58.61M |
Cash Flow | ||||||
| Free Cash Flow | 55.30M | 59.23M | 72.65M | 13.21M | 3.75M | -32.88M |
| Operating Cash Flow | 58.01M | 62.09M | 74.36M | 14.24M | 7.06M | -32.02M |
| Investing Cash Flow | -2.89M | -2.86M | -1.01M | -1.03M | 91.65M | 3.58M |
| Financing Cash Flow | -11.83M | -21.43M | -13.16M | -57.30M | -45.25M | 16.64M |
Basilea Pharmaceutica Technical Analysis
Positive
52.60
Price Trends
54.01
Positive
53.55
Positive
53.10
Positive
Market Momentum
3.48
Negative
83.82
Negative
93.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BSLN, the sentiment is Positive. The current price of 52.6 is below the 20-day moving average (MA) of 56.21, below the 50-day MA of 54.01, and below the 200-day MA of 53.10, indicating a bullish trend. The MACD of 3.48 indicates Negative momentum. The RSI at 83.82 is Negative, neither overbought nor oversold. The STOCH value of 93.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BSLN.
Basilea Pharmaceutica Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | CHF802.36M | 15.38 | ― | ― | 4.74% | -28.96% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | CHF137.68M | -2.65 | -66.19% | ― | -100.00% | 24.46% | |
49 Neutral | CHF259.66M | -19.33 | 277.88% | ― | -63.05% | -187.61% | |
44 Neutral | CHF232.91M | -4.10 | 684.83% | ― | 97.32% | -11.07% | |
41 Neutral | CHF28.66M | -2.13 | -49.18% | ― | ― | ― | |
32 Underperform | CHF1.47B | -4.33 | ― | ― | -8.06% | -87.00% |
* General Sector Average
CH:BSLN
Basilea Pharmaceutica
65.50
18.75
40.11%
CH:MOLN
Molecular Partners AG
3.60
0.63
21.01%
CH:IDIA
Idorsia Ltd
5.68
2.98
110.58%
CH:NWRN
Newron Pharmaceuticals SpA
12.22
3.34
37.61%
CH:SANN
Santhera Pharmaceuticals Holding
15.66
1.84
13.31%
CH:MMTX
MindMaze Therapeutics Holding SA
0.16
-2.54
-94.25%
Basilea Pharmaceutica Corporate Events
Basilea lifts 2026 profit outlook as anti-infectives pipeline and Cresemba sales power H1 results
Aug 18, 2026
Basilea Pharmaceutica reported a strong first half of 2026, with total revenue rising 14.4% to CHF 119 million and operating profit climbing 31.7% to CHF 31.6 million, driven largely by global demand for Cresemba and growing U.S. uptake of Zevtera...
Basilea Wins More BARDA Funding for Novel Oral Antibiotic Targeting Drug‑Resistant UTIs
Aug 5, 2026
Basilea Pharmaceutica has secured an additional USD 5.4 million in non‑dilutive funding from the U.S. Biomedical Advanced Research and Development Authority to advance its novel oral antibiotic Ceftibuten‑Ledaborbactam Etzadroxil. The ...
BARDA injects $30 million into Basilea’s phase 3 antifungal program
Jul 29, 2026
The U.S. Biomedical Advanced Research and Development Authority has released an additional USD 30 million in non‑dilutive funding to Basilea Pharmaceutica, after a predefined patient‑enrolment threshold was reached in a phase 3 clinica...
Basilea Wins Fresh BARDA Funding for Novel Oral Antibiotic to Tackle Drug-Resistant UTIs
May 28, 2026
Basilea Pharmaceutica has secured an additional USD 13.3 million in non-dilutive funding from the U.S. Biomedical Advanced Research and Development Authority to advance its novel oral antibiotic combination Ceftibuten-Ledaborbactam Etzadroxil for ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.